Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
Top Page
BioNTech SE
(NASDAQ:BNTX)
Rating:63Neutral
Price Target:
$119.00
▲(4.83% Upside)
Positive Factors
Financial Performance
BioNTech reported 2Q revenue well ahead of Street expectations, reaffirming full year guidance, indicating strong financial performance.
Oncology Development
BioNTech's BNT327 is positioned to become a future backbone in treating PD-L1 resistant tumors, highlighting its potential impact in oncology.
Negative Factors
COVID-19 Market Dynamics
Potential risks with US booster adoption and evolving policy shifts could impact BioNTech's near-term COVID revenues.
Regulatory Risks
There is meaningful downside risk following Dr. Vinay Prasad’s exit at FDA’s Center for Biologics Evaluation and Research, especially if FDA manages to carve vaccine leadership out from the rest of CBER.
BioNTech SE (BNTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.09B
Dividend YieldN/A
Average Volume (3M)644.18K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth7.51%
EPS Growth30.53%
CountryUS
Employees6,772
SectorHealthcare
Sector Strength49
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.87
Shares Outstanding240,398,730
10 Day Avg. Volume735,610
30 Day Avg. Volume644,179
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue3.62
Enterprise Value/Gross Profit4.56
Enterprise Value/Ebitda-23.02
Forecast
1Y Price Target
$138.89Price Target Upside22.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
BioNTech SE Business Overview & Revenue Model
Company DescriptionBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
How the Company Makes MoneyBioNTech generates revenue primarily through the commercialization of its products, particularly its COVID-19 vaccine, which has been a significant source of income due to global demand and government contracts. The company has established key partnerships, notably with Pfizer, which has enabled it to scale production and distribution effectively. In addition to vaccine sales, BioNTech is also involved in research collaborations and licensing agreements, allowing it to earn milestone payments and royalties from its developed therapies. The diversification of its product pipeline, including cancer therapies and other mRNA-based treatments, further contributes to its revenue stream by targeting various therapeutic areas and expanding its market reach.
BioNTech SE Earnings Call Summary
Earnings Call Date:Aug 04, 2025
(Q2-2025)
| % Change Since: 5.76%|
Next Earnings Date:Nov 03, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted BioNTech's strategic advancements and strong financial position, with significant partnerships and acquisitions enhancing their pipeline and capabilities. However, challenges remain, including a net loss, reduced COVID-19 vaccine uptake, and a missed trial endpoint in the melanoma study. While the company is making positive strides, the financial losses and COVID-19 challenges present notable hurdles.Q2-2025 Updates
Positive Updates
Increased Revenues
Total revenues for Q2 2025 reached approximately EUR 261 million, compared to EUR 129 million in the same period of 2024, mainly driven by higher revenues from the COVID-19 vaccine collaboration.
Strong Strategic Partnerships
BioNTech entered a global 50-50 co-development and co-commercialization collaboration with Bristol-Myers Squibb (BMS) to accelerate the clinical development of BNT327.
BNT327 Development and Progress
Initiated two global pivotal clinical trials in small cell and non-small cell lung cancer. The company plans to start a Phase III trial in triple-negative breast cancer later this year.
Robust Financial Position
BioNTech maintained a strong financial position with EUR 16 billion in cash plus security investments.
Strategic Acquisitions and Expansions
Completed the acquisition of Biotheus and announced a strategic transaction to acquire CureVac, enhancing mRNA capabilities.
Expansion in the UK
Expanded partnership with the UK government, planning to invest up to GBP 1 billion over the coming decade in regional R&D activities.
Negative Updates
Net Loss Reduction but Still Significant
Reported a net loss of EUR 387 million for Q2 2025, compared to a net loss of EUR 808 million for the same period in 2024.
COVID-19 Vaccine Revenue Challenges
Lower COVID-19 vaccination rates are anticipated compared to the prior year, affecting revenue expectations.
Decline in R&D and SG&A Expenses
Research and development expenses decreased to EUR 509 million from EUR 585 million, and SG&A expenses decreased to EUR 138 million from EUR 184 million compared to the same period last year, indicating reprioritization.
Challenges in Melanoma Trial
Phase II trial evaluating Autogene cevumeran in combination with pembrolizumab did not meet its primary endpoint of a statistically significant improvement in progression-free survival.
Company Guidance
During BioNTech's second quarter 2025 earnings call, the company provided detailed guidance on its strategic priorities and financial performance. Revenues for the quarter reached approximately €261 million, a significant increase from €129 million in the same period in 2024, driven primarily by the COVID-19 vaccine collaboration. The company maintained a strong financial position with €16 billion in cash and security investments. BioNTech reaffirmed its 2025 financial guidance, anticipating revenues between €1.7 billion and €2.2 billion, with R&D expenses projected between €2.6 billion and €2.8 billion. The company is focusing on its oncology pipeline, particularly the BNT327 bispecific antibody and mRNA cancer immunotherapies, FixVac and iNeST, with multiple Phase II and III trials underway. The strategic collaboration with BMS is expected to bring in $1.5 billion in upfront payments and up to $7.6 billion in potential milestones. Additionally, BioNTech is preparing for the global rollout of a new COVID-19 vaccine variant, pending regulatory approvals, and is investing in mRNA technology through the acquisition of CureVac.BioNTech SE Financial Statement Overview
Summary
BioNTech's financial performance is mixed. The balance sheet is strong with low debt levels, but income and cash flow statements show challenges in profitability and cash management. The company needs to address these issues for sustained growth.Income Statement
BioNTech's income statement reflects significant challenges in profitability. Recent TTM figures show negative net and EBIT margins, indicating operational inefficiencies. Although the company had strong revenue in previous years, recent declines highlight potential revenue instability.55
Neutral
Balance Sheet
BioNTech's balance sheet is robust, with a strong equity base and low levels of debt, resulting in a favorable debt-to-equity ratio. The equity ratio remains solid, underscoring financial stability. However, recent trends in reduced stockholders' equity warrant caution.70
Positive
Cash Flow
The cash flow analysis reveals a volatile free cash flow trend, with recent TTM figures showing a significant decline. While operating cash flow remains positive, the substantial drop in free cash flow raises concerns about cash management efficiency.60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.73B | 2.75B | 3.82B | 17.31B | 18.98B | 482.32M |
| Gross Profit | 2.17B | 2.21B | 3.22B | 12.78B | 15.12B | -222.04M |
| EBITDA | -429.20M | -367.10M | 1.09B | 12.86B | 15.73B | -97.89M |
| Net Income | -772.73M | -665.30M | 930.30M | 9.43B | 10.29B | 15.20M |
Balance Sheet | ||||||
| Total Assets | 21.18B | 22.53B | 23.01B | 23.28B | 15.83B | 2.32B |
| Cash, Cash Equivalents and Short-Term Investments | 14.11B | 16.78B | 16.55B | 14.06B | 2.07B | 1.35B |
| Total Debt | 293.00M | 254.20M | 219.10M | 212.20M | 301.50M | 240.19M |
| Total Liabilities | 2.26B | 3.12B | 2.76B | 3.22B | 3.94B | 946.77M |
| Stockholders Equity | 18.93B | 19.41B | 20.25B | 20.06B | 11.89B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | -1.15B | -244.60M | 4.67B | 13.21B | 735.70M | -98.92M |
| Operating Cash Flow | -219.29M | 207.70M | 5.37B | 13.58B | 889.70M | -13.47M |
| Investing Cash Flow | 1.48B | -2.08B | -6.95B | -35.30M | -566.10M | -144.85M |
| Financing Cash Flow | -52.06M | -45.90M | -778.60M | -1.42B | 94.20M | 894.73M |
BioNTech SE Technical Analysis
Positive
113.52
Price Trends
109.52
Positive
104.06
Positive
108.68
Positive
Market Momentum
0.76
Negative
58.17
Neutral
74.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Positive. The current price of 113.52 is above the 20-day moving average (MA) of 111.43, above the 50-day MA of 109.52, and above the 200-day MA of 108.68, indicating a bullish trend. The MACD of 0.76 indicates Negative momentum. The RSI at 58.17 is Neutral, neither overbought nor oversold. The STOCH value of 74.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNTX.
BioNTech SE Risk Analysis
BioNTech SE disclosed 1 risk factors in its most recent earnings report. BioNTech SE reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioNTech SE Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | $14.45B | 11.54 | 26.08% | ― | 23.25% | 64.46% | |
74 Outperform | $39.88B | 30.71 | 24.75% | ― | 89.58% | ― | |
63 Neutral | $27.09B | ― | -1.81% | ― | 7.51% | 30.53% | |
61 Neutral | $3.54B | ― | -51.57% | ― | 730.42% | 31.63% | |
52 Neutral | $58.03B | ― | -257.82% | ― | 5.01% | -330.09% | |
51 Neutral | $7.46B | -0.16 | -46.00% | 2.25% | 22.82% | -2.28% | |
45 Neutral | $10.38B | ― | -27.50% | ― | -38.95% | 51.07% |
* Healthcare Sector Average
Performance Comparison
BNTX
BioNTech SE
113.52
23.59
26.23%
ALNY
Alnylam Pharma
448.91
174.43
63.55%
ARGX
Argenx Se
653.83
129.64
24.73%
GMAB
Genmab
23.31
-4.44
-16.00%
MRNA
Moderna
28.02
-61.94
-68.85%
SWTX
Springworks Therapeutics
46.99
10.03
27.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.